-
Something wrong with this record ?
Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)
M. Ceckova, J. Reznicek, B. Deutsch, MF. Fromm, F. Staud,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Benzoxazines pharmacology MeSH
- Madin Darby Canine Kidney Cells MeSH
- Cimetidine pharmacology MeSH
- Renal Elimination MeSH
- HEK293 Cells MeSH
- Reverse Transcriptase Inhibitors pharmacokinetics pharmacology urine MeSH
- Rats MeSH
- Lamivudine pharmacokinetics pharmacology urine MeSH
- Kidney metabolism MeSH
- Humans MeSH
- Metformin metabolism pharmacology MeSH
- Area Under Curve MeSH
- Half-Life MeSH
- Rats, Wistar MeSH
- Organic Cation Transport Proteins antagonists & inhibitors metabolism MeSH
- Multidrug Resistance-Associated Proteins antagonists & inhibitors metabolism MeSH
- Dogs MeSH
- ROC Curve MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Humans MeSH
- Male MeSH
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC0-∞ value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012457
- 003
- CZ-PrNML
- 005
- 20190409160255.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0202706 $2 doi
- 035 __
- $a (PubMed)30114293
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ceckova, Martina $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
- 245 10
- $a Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate) / $c M. Ceckova, J. Reznicek, B. Deutsch, MF. Fromm, F. Staud,
- 520 9_
- $a Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor used in first-line combination antiretroviral therapy (cART). It is usually administered with nucleoside reverse transcriptase inhibitors (NRTI), many of which are substrates of OCT uptake solute carriers (SLC22A) and MATE (SLC47A), P-gp (MDR1, ABCB1), BCRP (ABCG2), or MRP2 (ABCC2) efflux transporters. The aim of this study was to evaluate the inhibitory potential of efavirenz towards these transporters and investigate its effects on the pharmacokinetics and tissue distribution of a known Oct/Mate substrate, lamivudine, in rats. Accumulation and transport assays showed that efavirenz inhibits the uptake of metformin by OCT1-, OCT2- and MATE1-expressing MDCK cells and reduces transcellular transport of lamivudine across OCT1/OCT2- and MATE1-expressing MDCK monolayers. Only negligible inhibition of MATE2-K was observed in HEK-MATE2-K cells. Efavirenz also reduced the efflux of calcein from MDCK-MRP2 cells, but had a rather weak inhibitory effect on Hoechst 33342 accumulation in MDCK-MDR1 and MDCK-BCRP cells. An in vivo pharmacokinetic interaction study in male Wistar rats revealed that intravenous injection of efavirenz or the control Oct/Mate inhibitor cimetidine significantly reduced the recovery of lamivudine in urine and greatly increased lamivudine retention in the renal tissue. Co-administration with efavirenz or cimetidine also increased the AUC0-∞ value and reduced total body clearance of lamivudine. These data suggest that efavirenz is a potent inhibitor of OCT/Oct and MATE/Mate transporters. Consequently, it can engage in drug-drug interactions that reduce renal excretion of co-administered substrates and enhance their retention in the kidneys, potentially compromising therapeutic safety.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a plocha pod křivkou $7 D019540
- 650 _2
- $a benzoxaziny $x farmakologie $7 D048588
- 650 _2
- $a cimetidin $x farmakologie $7 D002927
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a poločas $7 D006207
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x metabolismus $7 D007668
- 650 _2
- $a lamivudin $x farmakokinetika $x farmakologie $x moč $7 D019259
- 650 _2
- $a buňky MDCK $7 D061985
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metformin $x metabolismus $x farmakologie $7 D008687
- 650 _2
- $a proteiny spojené s mnohočetnou rezistencí k lékům $x antagonisté a inhibitory $x metabolismus $7 D027425
- 650 _2
- $a proteiny přenášející organické kationty $x antagonisté a inhibitory $x metabolismus $7 D027701
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a eliminace ledvinami $7 D065667
- 650 _2
- $a inhibitory reverzní transkriptasy $x farmakokinetika $x farmakologie $x moč $7 D018894
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Reznicek, Josef $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
- 700 1_
- $a Deutsch, Birgit $u Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 700 1_
- $a Fromm, Martin F $u Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 700 1_
- $a Staud, Frantisek $u Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 13, č. 8 (2018), s. e0202706
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30114293 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190409160310 $b ABA008
- 999 __
- $a ok $b bmc $g 1391767 $s 1050762
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 13 $c 8 $d e0202706 $e 20180816 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20190405